MSOS, TRLV Slide After Hours As DEA Judge Pauses Cannabis Rescheduling Case

MSOS, an ETF, and TRLV, one of its holdings, fell about 8-9% after hours as a federal judge paused a cannabis rescheduling case. The delay impacts investors' expectations for near-term changes to marijuana's legal status, which could affect the industry.

Original reporting
Published Sep 29, 2026, 11:11 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 30, 2026, 12:18 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefMarket movers
Primary signal
$MSOS
Bearish
high confidence
Mentioned
$MSOS · $TRLV
Relevance
7/10
AlphAI data visualization · based on stocktwits.com
Decision brief

The 30-second read

$MSOSBearishHigh
01

Why it matters

The decision removes near‑term regulatory upside, prompting immediate sell pressure in both the ETF (MSOS) and its top holding (TRLV).

02

Market read

Regulatory delay creates short‑term downside for cannabis‑related equities, with broader sector implications.

03

What to watch

Potential for future FDA‑approved products to move to Schedule III could still support the sector despite the current delay.

Relevance 7/10Novelty 8/10Timing: after-hours today

Background

A DEA chief judge halted a pending case to reclassify marijuana from Schedule I to Schedule III, delaying a catalyst that had been expected to boost cannabis stocks and ETFs.

Company-level read

Ticker impact

$MSOSBearishHigh confidence
Context

MSOS fell about 8% after hours as the DEA judge paused the cannabis rescheduling case, removing a near‑term catalyst.

Expected impact

likely pressure as the market prices in the rescheduling delay

Evidence & confidence

The ETF’s largest holding, TRLV, also dropped sharply; the news removes a catalyst that had been priced in.

$TRLVBearishHigh confidence
Context

Trulieve Cannabis dropped roughly 9% in extended trading after the DEA judge paused the case, despite a modest gain in regular session.

Expected impact

likely pressure as investors adjust to the delayed rescheduling decision

Evidence & confidence

The stock’s after‑hours decline mirrors the ETF’s move and reflects the same regulatory uncertainty.

Market effects

Cannabis sector sentiment weakened as a key regulatory catalyst was delayed.

U.S. market participants are most affected; the news is U.S.-centric.

Limited global impact beyond U.S. cannabis equities and ETFs.

Counterpoint

The pause may be temporary; investors could view the dip as a buying opportunity if rescheduling eventually proceeds.

Key entities

  • AdvisorShares Pure US Cannabis ETF

    Ticker MSOS, tracks U.S. cannabis equities.

  • Trulieve Cannabis Corp.

    Ticker TRLV, a leading U.S. medical and adult‑use cannabis operator.

  • DEA Chief Judge Derek Julius

    Paused the rescheduling case, affecting market expectations.

Related articles

$TRLVHigh

Trulieve (TRLV) Q3 2026 Earnings Call Transcript

Trulieve (TRLV) reported Q3 2026 earnings exceeding guidance, with $230M revenue (4% YoY growth), 64% gross margin, and $89M adjusted EBITDA. The company benefited from federal rescheduling of medical marijuana to Schedule III, enabling DEA registration, tax relief, and NYSE listing. Trulieve also repaid $65M in debt, improving cash flow. The company is expanding in Georgia and Texas, with strategic initiatives focused on access, growth, and product portfolio.

$TRLVHigh

Trulieve Reports Third Quarter 2026 Results

Trulieve Cannabis Corp. (TRLV) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Trulieve Reports Third Quarter 2026 Results • Third quarter revenue of $230 million, with 64% gross margin • Cash flow from operations of $183 million and free cash flow of $120 million* in first nine months of 2026 • Received final DEA registrations pursuant to fina

High

Federal drug officials register Trulieve's medical marijuana dispensaries

Trulieve Cannabis Corp. reported Q3 2026 revenue of $230 million, with a 64% gross margin. The company received final DEA registrations for its medical marijuana dispensaries following the rescheduling of cannabis to Schedule III. Trulieve also repaid $65 million in mortgage notes and operates 208 retail dispensaries. CEO Kim Rivers highlighted milestones unlocked by the rescheduling, including tax benefits and NYSE listing.